Brokerages predict that Aimmune Therapeutics Inc (NASDAQ:AIMT) will report ($1.03) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have provided estimates for Aimmune Therapeutics’ earnings, with estimates ranging from ($1.11) to ($0.92). Aimmune Therapeutics reported earnings of ($0.95) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 8.4%. The business is expected to report its next quarterly earnings report on Thursday, February 27th.
According to Zacks, analysts expect that Aimmune Therapeutics will report full year earnings of ($3.97) per share for the current fiscal year, with EPS estimates ranging from ($4.11) to ($3.83). For the next fiscal year, analysts anticipate that the business will post earnings of ($3.54) per share, with EPS estimates ranging from ($3.84) to ($2.98). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that cover Aimmune Therapeutics.
Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($1.03). During the same quarter in the previous year, the company posted ($0.89) EPS.
AIMT has been the subject of several research analyst reports. Piper Jaffray Companies set a $60.00 target price on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Stifel Nicolaus raised shares of Aimmune Therapeutics to a “positive” rating in a research report on Monday, September 16th. BidaskClub raised shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday. Goldman Sachs Group set a $27.00 target price on shares of Aimmune Therapeutics and gave the stock a “hold” rating in a research report on Friday, October 25th. Finally, Wedbush reissued a “buy” rating on shares of Aimmune Therapeutics in a research report on Thursday, October 31st. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $43.11.
In related news, CFO Eric Bjerkholt purchased 1,550 shares of Aimmune Therapeutics stock in a transaction dated Wednesday, September 18th. The stock was bought at an average cost of $22.57 per share, with a total value of $34,983.50. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 13.75% of the company’s stock.
Several large investors have recently modified their holdings of AIMT. Marshall Wace North America L.P. bought a new stake in shares of Aimmune Therapeutics during the 1st quarter worth $32,000. Los Angeles Capital Management & Equity Research Inc. bought a new stake in Aimmune Therapeutics in the 2nd quarter valued at $212,000. Janney Montgomery Scott LLC bought a new stake in Aimmune Therapeutics in the 2nd quarter valued at $296,000. Aperio Group LLC bought a new stake in Aimmune Therapeutics in the 2nd quarter valued at $76,000. Finally, Wedbush Securities Inc. boosted its holdings in Aimmune Therapeutics by 99.4% in the 2nd quarter. Wedbush Securities Inc. now owns 22,057 shares of the biotechnology company’s stock valued at $459,000 after purchasing an additional 10,997 shares during the period. 82.31% of the stock is owned by institutional investors.
Aimmune Therapeutics stock traded up $1.79 during midday trading on Thursday, hitting $31.88. 1,081,036 shares of the stock were exchanged, compared to its average volume of 716,060. Aimmune Therapeutics has a 1 year low of $16.95 and a 1 year high of $31.90. The firm has a market cap of $1.86 billion, a P/E ratio of -8.69 and a beta of -0.03. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.64 and a quick ratio of 4.64. The company has a 50 day moving average price of $27.89 and a two-hundred day moving average price of $22.52.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Recommended Story: Basic Economics creates winners and losers
Get a free copy of the Zacks research report on Aimmune Therapeutics (AIMT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aimmune Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aimmune Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.